SCHEDULE 13G/A: OrbiMed Advisors LLC Discloses 5.6% Stake in Verastem, Inc. Common Stock

OrbiMed Advisors LLC has filed an amended Schedule 13G, reporting a 5.6% beneficial ownership stake in Verastem, Inc.'s common stock as of March 31, 2025.

Summary

• OrbiMed Advisors LLC, an investment adviser based in Delaware, has filed an Amendment No. 3 to Schedule 13G regarding its beneficial ownership in Verastem, Inc.
• As of March 31, 2025, OrbiMed Advisors LLC beneficially owns 2,862,448 shares of Verastem, Inc. common stock.
• This ownership represents 5.6% of the total class of Verastem, Inc. common stock.
• OrbiMed Advisors LLC holds shared voting power and shared dispositive power over all 2,862,448 shares.
• The filing certifies that the securities were not acquired or held for the purpose of changing or influencing the control of Verastem, Inc.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing disclosing beneficial ownership. It does not contain positive or negative operational or financial news for the issuer, Verastem, Inc.

Positives

• The disclosure indicates continued institutional interest in Verastem, Inc. by OrbiMed Advisors LLC, a prominent investment adviser specializing in healthcare.

Future Outlook

NA

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

This filing indicates that OrbiMed Advisors LLC, a specialized healthcare investment firm, maintains a significant stake in Verastem, Inc., a biotechnology company. This suggests continued confidence or strategic positioning within the healthcare and pharmaceutical investment landscape by a key industry player.

Comparison to Industry Standards

• This document is a standard regulatory filing (Schedule 13G) for disclosing beneficial ownership exceeding 5%. It does not provide information for direct comparison of Verastem's performance or operations against industry benchmarks or specific comparable companies. The filing itself is a compliance document, not an operational or financial performance report.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake (5.6%) by OrbiMed Advisors LLC may be viewed positively by other shareholders, signaling institutional confidence or interest in Verastem, Inc.

Key Dates

Keywords

Verastem Inc, OrbiMed Advisors LLC, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Healthcare Investment, Institutional Ownership